Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

GlobeNewswire March 10, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 3, 2021

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 16, 2021

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

GlobeNewswire February 5, 2021

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

GlobeNewswire February 1, 2021

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

GlobeNewswire December 14, 2020

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001(TM) at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

GlobeNewswire December 5, 2020

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) in Sickle Cell Disease and Beta Thalassemia

GlobeNewswire December 1, 2020

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

GlobeNewswire November 24, 2020

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 16, 2020

CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

GlobeNewswire November 4, 2020

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

GlobeNewswire October 28, 2020

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110(TM) in Relapsed or Refractory CD19+ B-cell Malignancies

GlobeNewswire October 21, 2020

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

GlobeNewswire October 7, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 29, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001(TM) for the Treatment of Sickle Cell Disease

GlobeNewswire September 22, 2020

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

GlobeNewswire September 3, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire July 30, 2020

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire July 27, 2020

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

GlobeNewswire June 30, 2020